Sysmex (OTCMKTS:SSMXY) Shares Gap Down – Should You Sell?

Shares of Sysmex Corporation ADR (OTCMKTS:SSMXY) gapped down before the market opened on Monday . The stock had previously closed at $8.72, but opened at $8.36. Sysmex shares last traded at $8.37, with a volume of 3,981 shares traded.

Analysts Set New Price Targets

Separately, Citigroup downgraded shares of Sysmex from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 16th. One research analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold”.

Sysmex Price Performance

The company’s 50-day moving average price is $8.82 and its 200-day moving average price is $9.59. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.33 and a quick ratio of 2.44. The company has a market cap of $5.29 billion, a P/E ratio of 17.52 and a beta of 1.10.

Sysmex (OTCMKTS:SSMXY) last announced its earnings results on Thursday, February 12th. The company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.14 by $0.01. Sysmex had a net margin of 8.86% and a return on equity of 9.27%. The business had revenue of $837.32 million during the quarter, compared to analysts’ expectations of $819.99 million. As a group, sell-side analysts predict that Sysmex Corporation ADR will post 0.44 earnings per share for the current fiscal year.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.